BRAVECTO 112,5 mg SOLUCION PARA UNCION DORSAL PUNTUAL PARA GATOS PEQUEÑOS

Country: Spanja

Lingwa: Spanjol

Sors: AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

Ixtrih issa

Ingredjent attiv:

FLURALANER

Disponibbli minn:

Intervet International Bv

Kodiċi ATC:

QP53BX05

INN (Isem Internazzjonali):

FLURALANER

Għamla farmaċewtika:

SOLUCIÓN PARA UNCIÓN DORSAL PUNTUAL

Kompożizzjoni:

Excipientes: DIMETILACETAMIDA

Rotta amministrattiva:

USO CUTÁNEO

Tip ta 'preskrizzjoni:

Sujeto a prescripción veterinaria Bajo control ó supervisión del veterinario

Grupp terapewtiku:

Gatos pequeños

Żona terapewtika:

Fluralaner

Sommarju tal-prodott:

BRAVECTO 112,5 mg SOLUCION PARA UNCION DORSAL PUNTUAL PARA GATOS PEQUEÑOS, EU/2/13/158/018 - Caja con 1 Pipeta con 0,4 ml Autorizado Comercializado

L-istatus ta 'awtorizzazzjoni:

Autorizado

Data ta 'l-awtorizzazzjoni:

2016-06-09

Fuljett ta 'informazzjoni

                                [European Medicines Agency logo] European Medicines Agency - Science,
medicines, health [/]
    
Search for medicines ADVANCED DOCUMENT SEARCH
[/ema/index.jsp%3Fcurl=pages/document_library/landing/document_library_search.jsp]
MAIN NAVIGATION	*
Home [/ema/index.jsp%3Fcurl=pages/home/Home_Page.jsp&mid=]	*
Find medicine
[/ema/index.jsp%3Fcurl=pages/includes/medicines/medicines_landing_page.jsp&mid=]	*
Human regulatory
[/ema/index.jsp%3Fcurl=pages/regulation/landing/human_medicines_regulatory.jsp&mid=]	*
Veterinary regulatory
[/ema/index.jsp%3Fcurl=pages/regulation/landing/veterinary_medicines_regulatory.jsp&mid=]	*
Committees
[/ema/index.jsp%3Fcurl=pages/about_us/general/general_content_000217.jsp&mid=]	*
News & events
[/ema/index.jsp%3Fcurl=pages/news_and_events/landing/news_and_events.jsp&mid=]	*
Partners & networks
[/ema/index.jsp%3Fcurl=pages/partners_and_networks/general/general_content_000212.jsp&mid=]	*
About us
[/ema/index.jsp%3Fcurl=pages/about_us/document_listing/document_listing_000426.jsp&mid=]	*
HUMAN MEDICINES
[/../index.jsp%3Fcurl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124]	*
EUROPEAN PUBLIC ASSESSMENT REPORTS
[/../index.jsp%3Fcurl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d125]	*
EPARS: BACKGROUND AND CONTEXT
[/../index.jsp%3Fcurl=pages/medicines/general/general_content_000433.jsp&mid=WC0b01ac058067fa25]	*
PATIENT SAFETY
[/../index.jsp%3Fcurl=pages/medicines/landing/pha_listing.jsp&mid=WC0b01ac058001d126]	*
PENDING EC DECISIONS
[/../index.jsp%3Fcurl=pages/medicines/landing/smop_search.jsp&mid=WC0b01ac058001d127]	*
WITHDRAWN APPLICATIONS
[/../index.jsp%3Fcurl=pages/medicines/landing/wapp_search.jsp&mid=WC0b01ac058001d128]	*
PAEDIATRICS
[/../index.jsp%3Fcurl=pages/medicines/landing/pip_search.jsp&mid=WC0b01ac058001d129]	*
RARE DISEASE DESIGNATIONS
[/../index.jsp%3Fcurl=pages/medicines/landing/orphan_search.jsp&mid=WC0b01ac058001d12b]	*
MEDICINES UNDER EVALUATION
[/../index.jsp%3Fcurl=pages/medicines/document_listing/document_listing_000349.jsp&mid=WC0b01ac0580508
                                
                                Aqra d-dokument sħiħ
                                
                            

Karatteristiċi tal-prodott

                                [European Medicines Agency logo] European Medicines Agency - Science,
medicines, health [/]
    
Search for medicines ADVANCED DOCUMENT SEARCH
[/ema/index.jsp%3Fcurl=pages/document_library/landing/document_library_search.jsp]
MAIN NAVIGATION	*
Home [/ema/index.jsp%3Fcurl=pages/home/Home_Page.jsp&mid=]	*
Find medicine
[/ema/index.jsp%3Fcurl=pages/includes/medicines/medicines_landing_page.jsp&mid=]	*
Human regulatory
[/ema/index.jsp%3Fcurl=pages/regulation/landing/human_medicines_regulatory.jsp&mid=]	*
Veterinary regulatory
[/ema/index.jsp%3Fcurl=pages/regulation/landing/veterinary_medicines_regulatory.jsp&mid=]	*
Committees
[/ema/index.jsp%3Fcurl=pages/about_us/general/general_content_000217.jsp&mid=]	*
News & events
[/ema/index.jsp%3Fcurl=pages/news_and_events/landing/news_and_events.jsp&mid=]	*
Partners & networks
[/ema/index.jsp%3Fcurl=pages/partners_and_networks/general/general_content_000212.jsp&mid=]	*
About us
[/ema/index.jsp%3Fcurl=pages/about_us/document_listing/document_listing_000426.jsp&mid=]	*
HUMAN MEDICINES
[/../index.jsp%3Fcurl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124]	*
EUROPEAN PUBLIC ASSESSMENT REPORTS
[/../index.jsp%3Fcurl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d125]	*
EPARS: BACKGROUND AND CONTEXT
[/../index.jsp%3Fcurl=pages/medicines/general/general_content_000433.jsp&mid=WC0b01ac058067fa25]	*
PATIENT SAFETY
[/../index.jsp%3Fcurl=pages/medicines/landing/pha_listing.jsp&mid=WC0b01ac058001d126]	*
PENDING EC DECISIONS
[/../index.jsp%3Fcurl=pages/medicines/landing/smop_search.jsp&mid=WC0b01ac058001d127]	*
WITHDRAWN APPLICATIONS
[/../index.jsp%3Fcurl=pages/medicines/landing/wapp_search.jsp&mid=WC0b01ac058001d128]	*
PAEDIATRICS
[/../index.jsp%3Fcurl=pages/medicines/landing/pip_search.jsp&mid=WC0b01ac058001d129]	*
RARE DISEASE DESIGNATIONS
[/../index.jsp%3Fcurl=pages/medicines/landing/orphan_search.jsp&mid=WC0b01ac058001d12b]	*
MEDICINES UNDER EVALUATION
[/../index.jsp%3Fcurl=pages/medicines/document_listing/document_listing_000349.jsp&mid=WC0b01ac0580508
                                
                                Aqra d-dokument sħiħ